Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib maintenance monotherapy after first-line platinum chemotherapy in BRCA-mutated advanced ovarian cancer
NL-OMON59962Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Olaparib maintenance monotherapy with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Nov 2013; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON59962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59962.